Trial Profile

Randomized Phase III Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine/daunorubicin (Primary) ; Cytarabine; Daunorubicin
Indications Acute myeloid leukaemia
Focus Therapeutic Use

Most Recent Events

06 Nov 2024 Planned End Date changed from 1 Mar 2024 to 1 Jun 2027.
06 Nov 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Jun 2027.
03 Dec 2021 Planned number of patients changed from 593 to 882.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com